Yarrow Bioscience, Inc. (YARW)

Yarrow Bioscience, Inc. is a clinical-stage biotechnology company whose common stock trades on the Nasdaq. The company is focused on developing therapies for thyroid-related autoimmune and endocrine disorders, an area that includes conditions such as Graves' disease and thyroid eye disease.

Its programs are aimed at targeting the biology that drives these diseases at its source, with the goal of offering alternatives to existing treatments. Yarrow became publicly traded through a transaction with a previously listed biotechnology company; details on its pipeline, clinical status and headquarters are provided in its SEC filings.